GlassScriptPhysician profile
Morgan P Powers
NPI 1881161859
$2,365.93
in general payments reported to CMS, 2019-2025
29 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $551 · 2023: $480 · 2024: $570 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corium, LLC | $237.18 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $221.41 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $195.67 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.30 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $146.59 | 2021-2024 | |
| Amgen INC. | $145.49 | 2021-2022 | |
| Pfizer INC. | $126.12 | 2021-2025 | |
| Exact Sciences Corporation | $104.10 | 2023-2025 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $78.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.22 | 2021-2024 | Aralast, Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.86 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $67.59 | 2024-2025 | Auvelity |
| Lundbeck LLC | $63.86 | 2022-2024 | Vyepti |
| Lilly USA, LLC | $47.90 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.66 | 2022-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $35.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.89 | 2025 | Voquezna |
| Dexcom, INC. | $22.77 | 2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $21.42 | 2022 | |
| Glaxosmithkline, LLC. | $17.78 | 2024 | Arexvy, Shingrix |
| Horizon Therapeutics Plc | $16.67 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.08 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $14.63 | 2021 | |
| Eagle Pharmaceuticals, INC. | $14.60 | 2024 | |
| Antares Pharma, INC. | $14.48 | 2023 | Nocdurna, Tlando, Xyosted |
| Kowa Pharmaceuticals America, INC. | $13.41 | 2024 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.